Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 6

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 common stock under incentive award plan1,175 1 10,321 — — — 10,322 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(526)— — (19,704)— — (19,704)Repurchase of common stock in connection with Stock Repurchase Program(344)— — (11,710)— — (11,710)Stock-based compensation— — 14,286 — — — 14,286 Vesting of RSAs in connection with ESPP— — 698 — — — 698 Other comprehensive income, net of tax— — — — 1,487 — 1,487 Net income— — — — — 47,213 47,213 Balance at September 30, 2024104,703 $135 $806,317 $(682,177)$1,571 $512,989 $638,835 

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

CORCEPT THERAPEUTICS INCORPORATED

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation and Summary of Significant Accounting Policies

Description of BusinessCorcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us,” and “our”) is a commercial-stage biopharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym® (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. In June 2024, we made an authorized generic version of Korlym available. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a